1. Interleukin-5–producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy
- Author
-
Van Gool, Frédéric, Molofsky, Ari B, Morar, Malika M, Rosenzwajg, Michelle, Liang, Hong-Erh, Klatzmann, David, Locksley, Richard M, and Bluestone, Jeffrey A
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Autoimmune Disease ,2.1 Biological and endogenous factors ,Inflammatory and immune system ,Animals ,Antibodies ,Cell Proliferation ,Eosinophilia ,Humans ,Immunity ,Innate ,Interleukin-2 ,Interleukin-5 ,Lymphocytes ,Mice ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Paediatrics and Reproductive Medicine ,Biochemistry and cell biology ,Cardiovascular medicine and haematology ,Paediatrics - Abstract
Interleukin (IL)-2 promotes regulatory T-cell development and function, and treatment with IL-2 is being tested as therapy for some autoimmune diseases. However, patients receiving IL-2 treatment also experience eosinophilia due to an unknown mechanism. Here, we show that patients receiving low-dose IL-2 have elevated levels of serum IL-5, and this correlates with their degree of eosinophilia. In mice, low-dose IL-2-anti-IL-2 antibody complexes drove group 2 innate lymphoid cells (ILC2) to produce IL-5 and proliferate. Using genetic approaches in mice, we demonstrate that activation of ILC2 was responsible for the eosinophilia observed with IL-2 therapy. These observations reveal a novel cellular network that is activated during IL-2 treatment. A better understanding of the cross talk between these cell populations may lead to more effective targeting of IL-2 to treat autoimmune disease.
- Published
- 2014